Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

MMSI - Merit Medical Systems, Inc. So'nggi... | Finranks

Home

MMSI

M

Merit Medical Systems, Inc. (MMSI)

NMS – Real vaqt narxi. Valyuta: USD

68.73

-0.58 (-0.84%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

68.50

-0.23 (-0.33%)

Bozordan keyin: Mar 27, 2026, 5:00 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Videolar

No Data

There is no data to display

Press-relizlar

Medtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerte™ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain

Medtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerte™ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain

Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain GALWAY, Ireland, March 24, 2026 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today announced that it has entered into a distribution agreement with Merit Medical Systems, Inc. (NASDAQ: MMSI), to offer FDA-cleared ViaVerte™ — a minimally invasive and implant free basivertebral nerve ablation (BVNA) system. It is the first and only BVNA system with a physician-controlled steerable mechanism for precise basivertebral nerve targeting for treating chronic vertebrogenic lower back pain.

Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent

Merit Medical Launches the Resilience Through-the-Scope Esophageal Stent

New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures New Resilience™ deployment system, anti-migration stent design, and unique stent sizes offer physicians control while enhancing treatment for patients with esophageal fistulas and malignant strictures

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025

SOUTH JORDAN, Utah, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced that its Board of Directors unanimously appointed F. Ann Millner, Ed.D., formerly Merit's Lead Independent Director, as Chair of the Board effective January 5, 2026.

Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial

Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial

SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous Endovascular Interventional Strategies (VEINS) conference held in Las Vegas, NV.